{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-24-000069","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.770425+00:00","generated_at":"2026-06-03T14:24:23.077980+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA clears IND for Centessa's ORX750 Phase 1 trial in narcolepsy; PoC data expected 2H 2024","bullets":["FDA cleared IND for ORX750, an oral OX2R agonist targeting narcolepsy type 1 (NT1), NT2, and idiopathic hypersomnia.","Phase 1 study includes SAD, MAD, and cross-over PoC using Maintenance of Wakefulness Test and Karolinska Sleepiness Scale in sleep-deprived healthy volunteers.","FDA-set maximum exposure limit significantly exceeds predicted efficacious doses; no impact on planned development.","Dosing to begin imminently; proof-of-concept data anticipated in second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-24-000069","json":"https://secwatch.observer/filing/0001847903-24-000069.json","markdown":"https://secwatch.observer/filing/0001847903-24-000069.md","text":"https://secwatch.observer/filing/0001847903-24-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000069/0001847903-24-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000069/cnta-20240422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T14:24:23.077980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}